EU CTR Labeling and QP Release: What Global Sponsors Need to Get Right in Europe

For sponsors running global trials, Europe is rarely the hardest region clinically — but it's often the one where supply timelines quietly slip. The causes are usually the same two: labels that don't meet EU requirements for every participating member state, and batches that reach an EU depot before the release chain is complete. Neither is exotic. Both are predictable. And both can hold perfectly good drug on a shelf while sites wait.

Since the EU Clinical Trials Regulation (Regulation (EU) No 536/2014) became fully applicable — it applied from January 2022, and the transition period for ongoing trials ended in January 2025 — every clinical trial in the EU runs under a single framework. Here's what that means for supply.

Note: this article is a practical overview, not legal advice. Requirements are detailed and periodically updated; confirm specifics against current EU and national guidance for your study.

What does the EU CTR require on IMP labels?

Annex VI of the Regulation sets out the labeling particulars for investigational and auxiliary medicinal products. For an unauthorised IMP, labels typically need to identify the sponsor and contact point, the trial, the product (name or code, strength, dosage form, route), the quantity, batch or code number, storage conditions, the use-by date, and the statements that the product is for clinical trial use only.

The practical complications for global supply are:

• Language. Labels must be in the official language(s) of each member state where the product is used, as determined by that member state. A multi-country EU study can easily require several languages — which is why booklet labels are so common in European supply.
• Immediate vs outer packaging. Annex VI distinguishes what must appear on outer packaging and what can be reduced on small immediate containers, such as blisters or small vials. Kit design has to accommodate both.
• Authorised products. Where an IMP or auxiliary product is already authorised and used within its authorisation, lighter labeling requirements can apply — useful for comparators and background therapy, but only if the conditions are actually met.

Our packaging and labeling strategy post covers how to design for this kind of multi-language flexibility.

What are auxiliary medicinal products, and how are they labeled?

The CTR introduced the term auxiliary medicinal product (AxMP) for medicines used in a trial as described in the protocol but not as the investigational product — premedications, challenge agents, rescue medication, and background treatment are typical examples. Authorised AxMPs used within their authorisation can generally carry their normal commercial labeling, while unauthorised AxMPs carry specific requirements under Annex VI.

For supply teams, the lesson is that "ancillary" items can carry regulatory obligations in the EU. They need to be classified early — not discovered at depot receipt. We cover the wider set of auxiliary medicinal products and ancillaries in a separate post.

What is QP certification, and why does it gate EU supply?

In the EU, every batch of investigational medicinal product must be certified by a Qualified Person (QP) before it can be used in a trial. The QP confirms that the batch was manufactured and checked in accordance with GMP standards for IMPs — the Commission Delegated Regulation (EU) 2017/1569 and the associated EU guidelines on good manufacturing practice for investigational medicinal products, which superseded the old Annex 13 for trials under the CTR.

For product made outside the EU, certification is performed by a QP of the EU importing site, who must be satisfied that manufacture met standards at least equivalent to EU GMP. That usually means the QP needs documentation — batch records, certificates, audit evidence, and a clear chain of custody — well before the shipment arrives. Late paperwork is the most common reason imported batches sit in quarantine.

Many sponsors also operate a separate "regulatory release" step after QP certification: confirming that the trial is authorised in the destination country and that any conditions are met before product is released to sites. Whether formally named or not, this two-step logic — the batch is compliant and the trial is ready to receive it — should be explicit in your process.

Our GMP vs GDP post explains where manufacturing obligations end and distribution obligations begin.

Where do global supply plans usually trip up in Europe?

In our experience, the same five issues recur:

1. QP documentation arrives late. The batch lands at the EU depot; the QP dossier doesn't. Build the QP's documentation requirements into the manufacturing and shipping plan, with named owners and dates.
2. Label languages are finalised after countries change. A country added late means a label that doesn't cover it. Booklets with spare language capacity, or a planned relabeling route, avoid a full repack.
3. Expiry updates aren't planned. Extending shelf life on product already in the field requires a controlled relabeling process. Decide the approach before the first extension is needed — see our guide to expiry updates.
4. Auxiliary products aren't classified. Premeds or rescue therapies are treated as commodities until someone asks how they're labeled.
5. The UK and Switzerland are treated as "EU". Neither is part of the EU framework: the UK has operated its own clinical trials and QP regime since Brexit, and Switzerland has its own. Separate release and import pathways need their own timelines. And the wider picture of customs and import planning applies at every border.

How should sponsors structure EU supply to avoid delays?

• Choose the EU importing site and QP early, and agree the documentation package they'll need.
• Design labels for the full EU country list plus contingency, with the language and content matrix owned by regulatory and supply jointly.
• Map every product in the protocol — IMP, comparator, AxMP, ancillaries — to its EU classification and labeling requirement.
• Put certification and release in the timeline as explicit steps with realistic durations, not as assumed zero-time events.
• Plan expiry extensions and relabeling before first shipment.